Pablo Álvarez Vega - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 28, 2019

Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective StudySergio Cadenas-Menéndez, Pablo Álvarez Vega, Armando Oterino Manzanas, et al.

International Journal of Cardiology|October 15, 2018

Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registryRoberto Del Pozo, Isabel Blanco, Ignacio Hernández-González, et al.

Biomedicines|May 4, 2026

Baseline Composite Score for 12-Month Clinical Remission in Biologic-Treated Severe Asthma: Development of the Base4ScoreJuan Luis García-Rivero, Adil Hannaoui Anaaoui, Abel Pallarés-Sanmartín, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 28, 2019

Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective StudySergio Cadenas-Menéndez, Pablo Álvarez Vega, Armando Oterino Manzanas, et al.

International Journal of Cardiology|October 15, 2018

Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registryRoberto Del Pozo, Isabel Blanco, Ignacio Hernández-González, et al.

Biomedicines|May 4, 2026

Baseline Composite Score for 12-Month Clinical Remission in Biologic-Treated Severe Asthma: Development of the Base4ScoreJuan Luis García-Rivero, Adil Hannaoui Anaaoui, Abel Pallarés-Sanmartín, et al.

Pageof 1